Pre-made Zanolimumab benchmark antibody ( Whole mAb, anti-CD4 therapeutic antibody, Anti-IMD79/OKT4D Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-640
Pre-Made Zanolimumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Zanolimumab (expected trade name HuMax-CD4) is a human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma. Development of the drug was ultimately discontinued with termination of all trials.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Zanolimumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Psoriasis;Rheumatoid arthritis|
|Development Tech||Medarex HuMAb Mouse|